Listen to your gut: Antibodies against gut commensals predict type 1 diabetes onset and therapeutic responses to T cell modulation.

Immune responses to gut bacteria are associated with development of type 1 diabetes and predict the effectiveness of teplizumab, an anti-CD3 antibody, in delaying diabetes onset.